Agencies “failed miserably” over COX-2 inhibitorBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7483.113-a (Published 13 January 2005) Cite this as: BMJ 2005;330:113
- Barbara Kermode-Scott
North America's regulatory agencies have “failed miserably” in an important aspect of their public mandate, and new national agencies are needed to monitor drug safety, according to the Canadian Medical Association.
If the US Food and Drug Administration and Canada's regulatory agency, Health Canada, had used an active surveillance system that targeted serious adverse events, then the alarm over the cyclo-oxygenase-2 inhibitor rofecoxib (Vioxx) would have been sounded much earlier, says the association.
Both regulatory agencies put their emphasis and resources into assessing drug benefits, not harmful effects, states an editorial in the CMAJ (2005;172:5, 4 Jan). “The …
Log in using your username and password
Log in through your institution
Sign up for a free trial